On September 25, 2018, Claudia Lewis was quoted in an article in Law360 regarding how the Federal Trade Commission (FTC) for the first time is requiring a company to stop marketing its intravenous (IV) therapy "cocktails" as a treatment for serious diseases without scientific proof, signaling the agency has made false claims concerning health and safety an enforcement priority.
According to the article, the FTC's suit alleged A&O Enterprises Inc. and its owner Aaron K. Roberts made deceptive claims about its IV "cocktails" and their ability to treat ailments, including cancer, multiple sclerosis, and heart failure, in violation of the Federal Trade Commission Act. A settlement in the case prohibits the company from continuing to make those claims unless it can prove it has reliable scientific backing.
Ms. Lewis said, the gravity of claims made for the products for treating serious diseases also played a part in the FTC's decision to act quickly. "Any time you're talking about cancer patients or Alzheimer's or fibromyalgia, or what I consider to be serious disease conditions where people are probably undergoing fairly frequent allopathic care, the FTC is going to be very skeptical about whether there is substantiation for these types of products," she said.